Razelle Kurzrock

87.1k total citations · 29 hit papers
1.2k papers, 60.4k citations indexed

About

Razelle Kurzrock is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Razelle Kurzrock has authored 1.2k papers receiving a total of 60.4k indexed citations (citations by other indexed papers that have themselves been cited), including 616 papers in Oncology, 384 papers in Cancer Research and 357 papers in Molecular Biology. Recurrent topics in Razelle Kurzrock's work include Cancer Genomics and Diagnostics (320 papers), Lung Cancer Treatments and Mutations (176 papers) and Chronic Lymphocytic Leukemia Research (126 papers). Razelle Kurzrock is often cited by papers focused on Cancer Genomics and Diagnostics (320 papers), Lung Cancer Treatments and Mutations (176 papers) and Chronic Lymphocytic Leukemia Research (126 papers). Razelle Kurzrock collaborates with scholars based in United States, Netherlands and United Kingdom. Razelle Kurzrock's co-authors include Moshe Talpaz, Sandip Pravin Patel, David S. Hong, Shumei Kato, Aaron M. Goodman, Jordan U. Gutterman, Filip Jankú, Apostolia M. Tsimberidou, Hagop M. Kantarjian and Philip R Cohen and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Razelle Kurzrock

1.2k papers receiving 59.1k citations

Hit Papers

PD-L1 Expression as a ... 1986 2026 1999 2012 2015 2017 2008 1999 2017 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
    2015 1.8k citations Sandip Pravin Patel, Razelle Kurzrock Molecular Cancer Therapeutics profile →
  2. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
    2017 1.6k citations Aaron M. Goodman, Shumei Kato et al. Molecular Cancer Therapeutics profile →
  3. Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
    2008 1.1k citations Razelle Kurzrock et al. Clinical Cancer Research profile →
  4. The Biology of Chronic Myeloid Leukemia
    1999 975 citations Razelle Kurzrock et al. profile →
  5. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
    2017 789 citations Razelle Kurzrock et al. Cancer Treatment Reviews profile →
  6. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
    2020 746 citations Denis L. Jardim, Aaron M. Goodman et al. profile →
  7. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    2012 719 citations Gerald S. Falchook, Razelle Kurzrock et al. profile →
  8. The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
    1988 691 citations Razelle Kurzrock et al. profile →
  9. Autophagy as a target for anticancer therapy
    2011 680 citations Filip Jankú, David S. Hong et al. profile →
  10. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
    2017 648 citations Shumei Kato, Aaron M. Goodman et al. Clinical Cancer Research profile →
  11. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
    2015 589 citations Razelle Kurzrock et al. Clinical Cancer Research profile →
  12. Epstein-Barr Virus and Cancer
    2004 573 citations Razelle Kurzrock et al. Clinical Cancer Research profile →
  13. Liposome‐encapsulated curcumin
    2005 534 citations Razelle Kurzrock et al. Cancer profile →
  14. Liquid biopsy: current technology and clinical applications
    2022 501 citations Shumei Kato, Razelle Kurzrock et al. profile →
  15. Clinical toxicity of interferons in cancer patients: a review.
    1986 479 citations Razelle Kurzrock et al. Journal of Clinical Oncology profile →
  16. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    2011 445 citations Razelle Kurzrock, David S. Hong et al. Journal of Clinical Oncology profile →
  17. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
    2019 429 citations Shumei Kato, Scott M. Lippman et al. profile →
  18. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
    2012 424 citations Gerald S. Falchook, Razelle Kurzrock et al. The Lancet Oncology profile →
  19. Review of precision cancer medicine: Evolution of the treatment paradigm
    2020 418 citations Apostolia M. Tsimberidou, Razelle Kurzrock et al. Cancer Treatment Reviews profile →
  20. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
    2019 383 citations Funda Meric‐Bernstam, Charles Swanton et al. The Lancet Oncology profile →
  21. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
    2015 382 citations Gerald S. Falchook, Wells A. Messersmith et al. Journal of Clinical Oncology profile →
  22. HER2 expression status in diverse cancers: review of results from 37,992 patients
    2015 358 citations Min Yan, Razelle Kurzrock et al. profile →
  23. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →
  24. Novel patterns of response under immunotherapy
    2019 354 citations Razelle Kurzrock et al. profile →
  25. PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
    2016 354 citations Aaron M. Goodman, Sandip Pravin Patel et al. profile →
  26. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
    2017 322 citations Sadakatsu Ikeda, Razelle Kurzrock et al. profile →
  27. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    2021 251 citations Milind Javle, Mitesh J. Borad et al. The Lancet Oncology profile →
  28. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    2022 195 citations Shumei Kato, Mary Nesline et al. Cancer Treatment Reviews profile →
  29. Clinical trial design in the era of precision medicine
    2022 147 citations Apostolia M. Tsimberidou, Razelle Kurzrock et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Razelle Kurzrock United States 119 24.9k 21.0k 13.3k 12.3k 10.0k 1.2k 60.4k
Seth M. Steinberg United States 124 29.1k 1.2× 15.6k 0.7× 7.9k 0.6× 13.6k 1.1× 8.1k 0.8× 864 58.9k
Carlos Cordon‐Cardo United States 129 22.8k 0.9× 41.4k 2.0× 12.8k 1.0× 11.0k 0.9× 4.2k 0.4× 564 68.1k
Luis A. Díaz United States 84 14.6k 0.6× 13.1k 0.6× 13.9k 1.0× 6.5k 0.5× 14.1k 1.4× 419 40.3k
James G. Herman United States 119 15.1k 0.6× 50.9k 2.4× 13.6k 1.0× 7.6k 0.6× 8.6k 0.9× 399 65.8k
Stephen B. Baylin United States 131 16.0k 0.6× 60.4k 2.9× 13.8k 1.0× 6.5k 0.5× 7.6k 0.8× 444 77.0k
Donna Neuberg United States 113 14.0k 0.6× 14.4k 0.7× 4.4k 0.3× 4.1k 0.3× 11.3k 1.1× 719 46.3k
José Baselga United States 98 25.8k 1.0× 19.7k 0.9× 9.8k 0.7× 14.1k 1.1× 3.3k 0.3× 484 46.7k
Richard Pazdur United States 106 19.8k 0.8× 10.6k 0.5× 5.2k 0.4× 10.3k 0.8× 3.3k 0.3× 596 37.7k
Gabriel N. Hortobágyi United States 149 54.2k 2.2× 22.9k 1.1× 37.1k 2.8× 16.7k 1.4× 12.7k 1.3× 1.1k 88.3k
Howard A. Burris United States 89 25.4k 1.0× 13.0k 0.6× 6.2k 0.5× 10.7k 0.9× 3.8k 0.4× 741 38.2k

Countries citing papers authored by Razelle Kurzrock

Since Specialization
Citations

This map shows the geographic impact of Razelle Kurzrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Razelle Kurzrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Razelle Kurzrock more than expected).

Fields of papers citing papers by Razelle Kurzrock

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Razelle Kurzrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Razelle Kurzrock. The network helps show where Razelle Kurzrock may publish in the future.

Co-authorship network of co-authors of Razelle Kurzrock

This figure shows the co-authorship network connecting the top 25 collaborators of Razelle Kurzrock. A scholar is included among the top collaborators of Razelle Kurzrock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Razelle Kurzrock. Razelle Kurzrock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jia, Lesley Seymour, Jayesh Desai, et al.. (2025). Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. Journal of Clinical Oncology. 43(6). 735–747. 2 indexed citations
2.
Patel, Sandip Pravin, Megan Othus, Young Kwang Chae, et al.. (2023). A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clinical Cancer Research. 30(1). 33–38. 15 indexed citations
3.
Kurzrock, Razelle, Daisuke Nishizaki, Hirotaka Miyashita, et al.. (2023). Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer Medicine. 13(1). e6844–e6844. 9 indexed citations
4.
Subbiah, Vivek, Howard A. Burris, & Razelle Kurzrock. (2023). Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 130(2). 186–200. 16 indexed citations
5.
Javle, Milind, Mitesh J. Borad, Nilofer S. Azad, et al.. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. 22(9). 1290–1300. 251 indexed citations breakdown →
6.
Goodman, Aaron M., Ethan S. Sokol, Garrett M. Frampton, Scott M. Lippman, & Razelle Kurzrock. (2019). Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunology Research. 7(10). 1570–1573. 202 indexed citations
7.
Falchook, Gerald S., Razelle Kurzrock, Hesham M. Amin, et al.. (2019). First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1237–1246. 67 indexed citations
8.
Subbiah, Vivek & Razelle Kurzrock. (2018). Challenging Standard-of-Care Paradigms in the Precision Oncology Era. Trends in cancer. 4(2). 101–109. 54 indexed citations
9.
Cohen, Philip R., Shumei Kato, Aaron M. Goodman, Sadakatsu Ikeda, & Razelle Kurzrock. (2017). Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. International Journal of Molecular Sciences. 18(8). 1663–1663. 28 indexed citations
10.
Kato, Shumei, Scott M. Lippman, Keith T. Flaherty, & Razelle Kurzrock. (2016). The Conundrum of Genetic “Drivers” in Benign Conditions. JNCI Journal of the National Cancer Institute. 108(8). djw036–djw036. 102 indexed citations
11.
Henary, Haby, Goldy C. George, Jennifer J. Wheler, et al.. (2015). A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 76(3). 597–603. 1 indexed citations
12.
Yan, Min, Barbara A. Parker, Richard B. Schwab, & Razelle Kurzrock. (2014). HER2 aberrations in cancer: Implications for therapy. Cancer Treatment Reviews. 40(6). 770–780. 175 indexed citations
13.
Jardim, Denis L., Kenneth R. Hess, Patricia LoRusso, Razelle Kurzrock, & David S. Hong. (2013). Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs. Clinical Cancer Research. 20(2). 281–288. 39 indexed citations
14.
Zheng, Liang, Yan Long, Wen-Bin Tsai, et al.. (2012). Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. Molecular Cancer Therapeutics. 11(11). 2483–2494. 67 indexed citations
15.
Tsimberidou, Apostolia M., Nancy G. Iskander, David S. Hong, et al.. (2012). Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. Clinical Cancer Research. 18(22). 6373–6383. 387 indexed citations
16.
Wheler, Jennifer J., Apostolia M. Tsimberidou, David S. Hong, et al.. (2012). Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience. Clinical Cancer Research. 18(10). 2922–2929. 77 indexed citations
17.
Hong, David S., Daniel W. Bowles, Gerald S. Falchook, et al.. (2012). A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(15). 4173–4182. 134 indexed citations
18.
Moulder, Stacy L., John W. Moroney, Thorunn Helgason, et al.. (2011). Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. Journal of Clinical Oncology. 29(19). e572–e575. 54 indexed citations
19.
Jankú, Filip, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, et al.. (2011). PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors. Molecular Cancer Therapeutics. 10(3). 558–565. 289 indexed citations
20.
El‐Osta, Hazem, David S. Hong, Jennifer J. Wheler, et al.. (2011). Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience. The Oncologist. 16(9). 1292–1298. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seth M. Steinberg Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Luis A. Díaz Breakdown of academic impact, for papers by James G. Herman Breakdown of academic impact, for papers by Stephen B. Baylin Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Gabriel N. Hortobágyi Breakdown of academic impact, for papers by Howard A. Burris
Rankless by CCL
2026